San Diego-based Viscient Biosciences has announced collaboration with Organovo to help establish a disease model for Non-Alcoholic Fatty Liver (NAFL) disease in bio-printed 3D liver samples. The CEO Taylor Crouch stated that their 3D disease models have the unique capability to demonstrate drug mechanisms of action and efficacy in a setting that closely mimics human livers.
Viscient Biosciences partner with Ogranovo for 3D Bioprinting in Liver Disease Researh
- Details
- Written by Dr.Varun